Why the study?
Do thienopyridines (ticlopidine or clopidogrel) reduce the recurrence of vascular events compared to aspirin in patients at high risk of vascular disease?
Population
22,656 patients at high risk of vascular disease from 4 randomized trials. Qualifying events included recent…
Comparison
Thienopyridines (ticlopidine or clopidogrel) vs Aspirin
Design
Systematic_review
Follow-up
12 to 40 months
Authors
Loading...
Favors aspirin first-line in high-risk patients; confirms thienopyridines as suitable alternatives mainly for aspirin intolerance.
Do thienopyridines (ticlopidine or clopidogrel) reduce the recurrence of vascular events compared to aspirin in patients at high risk of vascular disease?
Thienopyridines offer only a modest benefit over aspirin for preventing serious vascular events in high-risk patients, making clopidogrel a suitable alternative primarily for those intolerant or allergic to aspirin.
Michael E. Ernst (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: